HUTCHMED (China) logo

HUTCHMED (China)

HCM | NASDAQ
Chart Builder DCF Calculator
$14.73
-$0.17 (-1.14%)
At close: Nov 16, 2026, 4:00 PM ET
$14.73
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET
-1.14%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
32.9
+0.2 pts
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #717/1021 (Top 70%)

Key Statistics

Market Data

Market Cap $2.57B
1D Range
14.66 14.84
52W Range
9.99 16.05

Valuation (TTM)

PE 147.30
PB 2.04
EV/EBITDA -62.78

Valuation (NTM)

Forward PE 39.21
Forward PEG -1.84
Price Target $16.25
Loading financial charts...

Profile

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related di...

Sector Healthcare
Employees 1,796
IPO Date Mar 16, 2016
Fiscal Year January - December

Latest News

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

1 day ago · globenewswire.com

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript

4 days ago · seekingalpha.com

HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

6 days ago · globenewswire.com

Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

12 days ago · prnewswire.com

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

12 days ago · globenewswire.com

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

15 days ago · globenewswire.com

HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026

18 days ago · globenewswire.com

Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

19 days ago · globenewswire.com

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

21 days ago · globenewswire.com

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

22 days ago · globenewswire.com

HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026

Earnings

Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Hold
Price Target
$16.25
Upside
+10.32%
Buy (1)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.